MRD-guided surveillance for advanced rectal cancer (SURVEILLANCE-III)
Part of Cancer, Digestive system clinical trials.
This trial tests whether a special blood test (MRD) can help monitor your rectal cancer after surgery, to catch any signs of remaining cancer early. It's for people with advanced but not metastatic rectal cancer that can be removed with surgery, and who haven't started any cancer treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a confirmed type of rectal cancer called adenocarcinoma (including certain specific types).
- Your tumor is located in the lower or middle part of the rectum, within about 4 inches of the anal opening and has not spread to other organs.
- You have not yet started any chemotherapy, radiation, or other cancer treatments for this rectal cancer.
- You are healthy enough (ECOG score 0 or 1) to undergo surgery to remove the tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (MRD) to monitor for cancer return after surgery in patients with stage IV colorectal cancer that can be removed. The goal is to catch any recurrence early and guide further treatment.
This study watches for signs of leftover cancer after surgery using a blood test (MRD). It is for people with early-stage colon cancer who have not yet had any treatment other than surgery.
This trial uses advanced MRI scans to see how well rectal cancer is responding to radiotherapy. It may help doctors better understand which treatments work best for patients with more advanced disease.
This trial is for people with stage III colorectal cancer who haven't had treatment yet. It tests a blood test to find tiny bits of cancer DNA (MRD) after surgery, which may help doctors know if more treatment is needed.
This trial uses a blood test (liquid biopsy) to look for tiny bits of cancer DNA remaining after surgery. It aims to see if this test can help guide follow-up and treatment decisions for people with colorectal cancer.
This study looks at whether a blood test for leftover cancer cells (called MRD) after stomach cancer surgery can help guide treatment. It is for people with a certain type of stomach cancer that has spread to nearby tissues but not to distant organs, and who are having surgery as their first treatment.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.